Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia. Many mutations favor active kinase conformations that preclude imatinib binding. Because the active forms of ABL and SRC resemble one another, we tested two dual SRC-ABL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Azam, Mohammad, Nardi, Valentina, Shakespeare, William C., Metcalf, Chester A., Bohacek, Regine S., Wang, Yihan, Sundaramoorthi, Raji, Sliz, Piotr, Veach, Darren R., Bornmann, William G., Clarkson, Bayard, Dalgarno, David C., Sawyer, Tomi K., Daley, George Q.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2006
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1482597/
https://ncbi.nlm.nih.gov/pubmed/16754879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0600001103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados